Peptide Dosage Chart: Complete 2026 Reference Guide
Medical disclaimer: This article is for educational purposes only and is not medical advice. Peptides discussed here are largely unapproved by the FDA, and human research is limited. Always consult a licensed physician before considering any peptide therapy. Never source peptides from unregulated online vendors.
Peptide searches have exploded. Queries like “peptide dosages,” “peptide dosage,” and “peptide dosing chart” pull tens of thousands of monthly searches, and most people asking are looking for one thing: a clear reference chart.
This guide provides that reference — but with an important distinction. Instead of prescribing dosages (which no article can responsibly do for unapproved compounds), it summarizes what published research has actually studied, flags where human data is thin, and tells you what to ask your doctor. For a broader introduction to what peptides are and how they work, see our complete peptide guide for beginners.
Quick-Reference Peptide Chart
The most-searched peptides, their categories, FDA status, and what published research has studied:
BPC-157 (Tissue repair) — Not FDA approved. Animal studies on tendon, gut, and nerve healing; only 3 small human pilot studies (under 30 subjects total). Liver toxicity signals in animal studies.
TB-500 / Thymosin Beta-4 (Tissue repair) — Not FDA approved. Animal studies on wound healing and cardiac repair; veterinary use in horses since the 1960s. No controlled human trials completed.
GHK-Cu (Skin/cosmetic) — Topical may be compounded with prescription; injectable not approved. Human RCTs on skin aging (71 women, 12 weeks): 55.7% wrinkle volume reduction vs control.
CJC-1295 (Growth hormone secretagogue) — Not FDA approved. Two randomized placebo-controlled trials (2006): GH rose 2-10x for 6+ days; IGF-1 rose 1.5-3x for 9-11 days. WADA-prohibited.
Ipamorelin (Growth hormone secretagogue) — Not FDA approved. Bowel surgery trial (117 patients): well tolerated, no better than placebo on primary endpoint. WADA-prohibited.
Semaglutide (GLP-1 weight loss/diabetes) — FDA-approved (Wegovy, Ozempic, Rybelsus). STEP trials: ~15% mean weight loss at 68 weeks. Nausea, GI effects; thyroid tumor boxed warning (rodent data).
Tirzepatide (Dual GIP/GLP-1) — FDA-approved (Zepbound, Mounjaro). SURMOUNT trials: ~20-22% mean weight loss at 72 weeks. SURMOUNT-5 head-to-head: 20.2% vs 13.7% semaglutide.
Retatrutide (Triple agonist) — Not approved (investigational). TRIUMPH trials: 28.3% weight loss at 80 weeks. 73 hospitalizations in FDA adverse-event database.
BPC-157: What the Research Shows
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide originally isolated from human gastric juice. It is the single most-searched research peptide, and the gap between its online reputation and its human evidence base is enormous.
Over 100 animal studies spanning three decades have reported effects on tendon healing, gut repair, nerve regeneration, and inflammation. But as of March 2026, only 3 published human studies exist, all small pilot studies with no placebo controls. The FDA placed BPC-157 on Category 2 in 2023, blocking compounding, and flagged concerns including immune reactions and a 2020 study showing liver toxicity signals in rats and dogs.
TB-500 (Thymosin Beta-4): What the Research Shows
TB-500 is a synthetic version of thymosin beta-4, naturally present in virtually all human and animal cells. Animal studies show accelerated wound healing, cardiac progenitor cell activation after heart attack, and anti-inflammatory effects. No controlled human trials have been completed. One theoretical concern: its anti-apoptotic activity could encourage metastatic potential in tumor cells, though not demonstrated in humans. WADA-prohibited at all times.
GHK-Cu: What the Research Shows
GHK-Cu is the rare peptide in this list with genuine human randomized controlled trial data — for topical use. A 2015 double-blind trial (71 women, 12 weeks) found statistically significant improvements in fine-line depth, wrinkle severity, skin laxity, and skin thickness versus placebo. A 2022 RCT found 1% GHK-Cu cream reduced wrinkle volume by 55.7% and wrinkle depth by 32.8% versus control. Topical GHK-Cu may be legally compounded with a patient-specific prescription. Contraindications include copper metabolism disorders such as Wilson’s disease.
CJC-1295 and Ipamorelin: What the Research Shows
These growth hormone secretagogues are among the few research peptides with published placebo-controlled human trials — though the trials measured hormone levels, not clinical outcomes. In 2006, two randomized, double-blind, placebo-controlled trials found a single CJC-1295 injection raised growth hormone 2- to 10-fold for 6+ days. No controlled human trial has shown benefit for muscle growth, fat loss, recovery, or anti-aging for either peptide. Both are WADA-prohibited.
FDA-Approved Peptides: Semaglutide and Tirzepatide
Unlike everything above, semaglutide and tirzepatide are FDA-approved medicines with large randomized trial programs. Semaglutide (Wegovy, Ozempic) showed ~15% mean weight loss at 68 weeks; the newer 7.2 mg dose reached 20.7% at 72 weeks. Tirzepatide (Zepbound, Mounjaro) showed ~20-22% mean weight loss at 72 weeks, beating semaglutide head-to-head (20.2% vs 13.7%). Both carry a boxed warning for thyroid C-cell tumors (rodent data) and common GI side effects.
Why “Dosage Charts” From Vendors Are Dangerous
Most dosage charts circulating online are published by peptide vendors or forums, not medical sources. The FDA has warned that products sold as “research use only” while marketed with human-use claims are illegal. Injectable products of unknown strength and purity pose infection risks, dosing unpredictability, and contamination hazards. The FDA’s adverse-event database logged 73 hospitalizations connected to gray-market retatrutide.
What to Ask Your Doctor
- Which peptides (if any) are FDA-approved for my specific concern?
- What does the human evidence actually show — not animal studies?
- What are the known and unknown risks for my health history?
- How would we monitor safety?
- Are there approved alternatives with better evidence?
- Is this peptide legal to prescribe and compound in my state?
The Bottom Line
Search interest in peptide dosages is enormous, but the human evidence base for most research peptides is thin. The two exceptions with real human trial data are GHK-Cu (topical, for skin) and the FDA-approved GLP-1 medicines. For everything else: talk to a doctor, demand evidence, and never inject substances of unknown origin.
This article is educational content, not medical advice. Consult a licensed physician before making any decisions about peptide therapy.
Interested in Peptides?
If you’re interested in exploring peptide therapy, click here to learn more.
